Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $1,411,130.70 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 79,590 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $17.73, for a total value of $1,411,130.70. Following the sale, the insider owned 315,978 shares in the company, valued at approximately $5,602,289.94. This trade represents a 20.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Francis Lo also recently made the following trade(s):

• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.08, for a total transaction of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.50, for a total transaction of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.57, for a total value of $1,773,267.30.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT traded down $0.03 during mid-day trading on Wednesday, hitting $18.04. The stock had a trading volume of 1,865,999 shares, compared to its average volume of 1,982,211. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -33.41 and a beta of 2.18. Adaptive Biotechnologies Corporation has a twelve month low of $6.26 and a twelve month high of $20.76. The company’s 50 day simple moving average is $16.50 and its 200 day simple moving average is $14.44.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The firm had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. During the same period in the prior year, the firm posted ($0.22) EPS. The company’s revenue for the quarter was up 102.4% on a year-over-year basis. As a group, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ADPT. Ameriprise Financial Inc. lifted its position in shares of Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares in the last quarter. Geode Capital Management LLC raised its position in Adaptive Biotechnologies by 15.6% during the second quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock worth $37,461,000 after acquiring an additional 434,347 shares during the period. Aristotle Atlantic Partners LLC raised its position in Adaptive Biotechnologies by 8.6% during the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock worth $46,776,000 after acquiring an additional 247,402 shares during the period. Fred Alger Management LLC grew its position in shares of Adaptive Biotechnologies by 6.7% in the third quarter. Fred Alger Management LLC now owns 2,514,234 shares of the company’s stock valued at $37,613,000 after purchasing an additional 158,807 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares during the period. 99.17% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on ADPT shares. JPMorgan Chase & Co. boosted their target price on Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Piper Sandler increased their price target on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. Guggenheim initiated coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 30th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Wall Street Zen upgraded Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.11.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.